DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
SEARCH
Ubicación actual:
>
> This Story


Conexión o Registro to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

CT Homepage

SEC probes Siemens, GE and Philips over business with China Lawsuit alleges OEMs worked together to fix prices on medical equipment

Study calls for better factoring-in of patient complexity in head CT scans Should consider complexity of associated billed patient encounters

Study shows 30 percent drop in unnecessary head CTs with BrainScope One May help ensure appropriate use of imaging

MR method could spare patients with skull lesions from CT, says study Could benefit children and pregnant women

FDA clears GE’s AI-based CT image reconstruction technology Available as upgrade to Revolution Apex scanner

First ultra high-res CT scan performed on US patient Scanner at UC Davis can image anatomy as small as 150 microns

Industrial hi-res X-ray yields greater insight into child abuse case Identified microscopic injuries that would not have been detected with standard CT

Trice Imaging connects imaging devices of large chain healthcare provider Aleris Patients and physicians can view images on laptops, cell phones

Reducing extravasations in CT contrast-enhanced IV injections Tips and best practices for administering better care

Researchers orchestrate malware attack to expose imaging vulnerabilities Deceived radiologists and AI algorithms into misdiagnoses

Philips' MRCAT pelvis can now be
used to create treatment plans for
cancers of the pelvis

FDA okays Philips' MR-only radiotherapy simulator, MRCAT pelvis

por John R. Fischer , Staff Reporter
The FDA has given Royal Philips the okay for its MR-only radiotherapy simulator, MRCAT pelvis (Magnetic Resonance for Calculating Attenuation), in the construction of treatment plans for cancer of the pelvis.

Already approved for planning in cases of prostate cancer, the extension of the solution into the pelvic region of the body is expected to provide clinicians with accurate radiotherapy treatment plans for cancers of the bladder, rectum, anus and cervix. It is one of many regions of the body where the Netherlands-based healthcare giant plans to eventually help create guidance for combating malignancies.

Story Continues Below Advertisement

THE (LEADER) IN MEDICAL IMAGING TECHNOLOGY SINCE 1982. SALES-SERVICE-REPAIR

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.



“An exciting potential area for the application of MR-only simulation is the brain, and this is something we're actively working on,” Ardie Ermers, general manager of radiation oncology at Philips, told HCB News. “By expanding the range of cancers for which the treatment planning can take place using MR-only simulation, we're making it more efficient and cost-effective for healthcare providers to deploy MR-only workflows.”

Most patients require a quick CT scan for recording tumor location and tissue density, factors which are important in determining the right radiation dose. They then must undergo MR scans for mapping the tumor and surrounding healthy tissue. Together, both scans can be time-consuming, expensive and create a complex workflow for clinicians, as well as form longer waiting gaps for the start of treatment.

Backed by studies, MRCAT is capable of constructing both soft tissue and density maps from one MR exam that are as accurate as plans based on CT. This eliminates the need for a CT scan, creates a simplified MR-only workflow that is cost-effective for providers, and brings the benefits of MR-only radiation therapy to a broader patient base.

MRCAT pelvis is available on the Philips wide bore digital Ingenia MR-RT platform, which made its debut in 2018 at the ASTRO Annual Meeting in San Antonio, Texas. https://www.dotmed.com/news/story/44953

The simulator, which was first released for prostate cancer radiotherapy planning in 2015, is used in routine clinical settings at several hospitals worldwide and has been used in the treatment planning for over 1000 patients.

“We’ve successfully implemented MR-only simulation in our clinical protocols for pelvic cancer patients,” said Professor Dr. Heikki Minn, of the radiation therapy department at Turku University Hospital in Finland, in a statement. “As a result, we’ve been able to improve efficiency, reduce dosimetric errors introduced by CT-MR registration, and save costs by decreasing redundant imaging.”

MRCAT pelvis is cleared for use by Health Canada and CE marked in Europe.

CT Homepage


You Must Be Logged In To Post A Comment

Advertise
Aumente su conciencia de marca
Subastas + ventas Privadas
Consigue el mejor precio
Comprar Equipo/Piezas
Encuentra El Precio Más Bajo
Noticias diarias
Lee las últimas noticias
Directorio
Examina todos los usuarios DOTmed
Ética en DOTmed
Ver nuestro programa de ética
El oro parte programa del vendedor
Recibir las solicitudes de PH
Programa de distribuidor con servicio gold
Recibe solicitudes
Proveedores de atención de salud
Ver todos los HCP (abreviatura de asistencia médica) Herramientas
Jobs/Entrenamiento
Encontrar/rellenar un trabajo
Parts Hunter +EasyPay
Obtener presupuestos para piezas
Recently Certified
Ver usuarios certificados recientemente
Recently Rated
Ver usuarios certificados recientemente
Central de alquiler
Alquila equipos por menos
Vende equipos/piezas
Obtén más dinero
Service Technicians Forum
Buscar ayuda y asesoramiento
Petición sencilla de propuestas
Obtén presupuestos para equipos
Feria comercial virtual
Encuentra servicio para el equipo
El acceso y el uso de este sitio está conforme a los términos y a las condiciones de nuestro AVISO LEGAL & AVISO DE LA AISLAMIENTO
Característica de y propietario DOTmeda .com, inc. Copyright ©2001-2019 DOTmed.com, Inc.
TODOS LOS DERECHOS RESERVADOS